Figure 1.
Plots of pulmonary vascular resistance before and after addition of parenteral prostacyclin (PGI2) in BMPR2 mutations carriers and non BMPR2 mutations carriers receiving background oral combination therapy
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.